Stabilised FMDV Capsids via VP2 Amino Acid Substitutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FMD vaccines face challenges due to the high variability and instability of foot-and-mouth disease virus (FMDV) serotypes, leading to limited cross-protection, short shelf-life, and the need for stringent bio-security and cold-chain logistics, which complicates vaccination efforts, especially in tropical and developing regions.
Innovation Solution
Development of an FMDV VP2 protein mutant with specific amino acid substitutions in the αA helix region, enhancing the biophysical stability of FMDV capsids, allowing for the production of more stable vaccines that can be used for all serotypes and reducing the need for strict cold-chain storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional FMD vaccines are used, then protective immunity is achieved, but the vaccines require strict cold-chain storage and have short shelf-life
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the VP2 protein through specific substitutions (e.g., position 93: Serine to Cysteine, Threonine to Cysteine, or Serine to Alanine). These parameter changes at the molecular level fundamentally alter the biophysical stability of the capsid structure, enabling the vaccine to maintain stability without strict cold-chain storage while preserving protective immunity.
2Reliability
If traditional FMD vaccines are used, then protective immunity is achieved, but stringent bio-security conditions are required during production
Solution Approach 1:
The patent extracts only the essential immunogenic component (the VP2 protein with specific amino acid substitutions) from the complete virus particle. By using a recombinant expression system to produce only this stabilized protein subunit, the invention eliminates the need for handling live or inactivated whole viruses during production, thereby reducing bio-security requirements while maintaining protective immunity.
3Adaptability or versatility
If FMDV capsids with high variability are used, then coverage of different serotypes is attempted, but cross-protection is limited
Solution Approach 1:
The patent applies local quality by making specific, targeted amino acid substitutions at particular positions (e.g., position 93) within the VP2 protein structure. These localized changes enhance the biophysical stability of the capsid without altering the antigenic determinants responsible for serotype-specific recognition, thereby maintaining cross-protection potential while improving vaccine stability.
Data Source
AI summary
The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.